Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Must-See Public Parks from Around the Globe - 2Building an Individual Brand: Illustrations from Forces to be reckoned with
- 3UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- 4Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- 5Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Vote In favor of Your Favored Kind Of Tea
- Instructions to Pick the Right Dental Expert for Teeth Substitution
- Figure out How to Reveal Stowed away Open Record Rewards
- First SpaceX booster for upgraded Starship fails during test in Texas
- Explainer-What has happened to the damaged spacecraft at China's space station?
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- Father and son spending Christmas together after health scares
